PharmiWeb.com - Global Pharma News & Resources

Today Stories

– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs. Merus is a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), referred to together as Multiclonics®, that are generated by a proprietary common…
– New Positive Clinical Data Demonstrate Momentum on Investigational Once-Daily, Once-Weekly and Twice-Yearly Dosing Strategies – – Key Findings from Studies Evaluating Potential Future Long-Acting Combination Regimens Affirm Commitment to Continuous Biomedical Innovation – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline. The latest results explore clinical outcomes from a study evaluating an investigational combination regimen of bictegravir and lenacapavir, new findings from a study evaluating the investigational combination of lenacapavir with broadly neutralizing antibodies (bNAbs), and new proof-of-concept data on GS-1720, a novel once-w…
First established in 2021, Abbott will continue as Global Health Sciences and Nutrition Partner of the Real Madrid Football Club and Global Partner of the Real Madrid Foundation through the club's 2026-2027 season Partnership aims to reduce childhood malnutrition and promote healthy habits for future generations Abbott has provided over 25,000 hours of nutrition education and screened over 3,000 children for malnutrition since the start of the partnership ABBOTT PARK, Ill. and MADRID, March 4, 2024— Abbott, Real Madrid and the Real Madrid Foundation announced today the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation. Abbott and…
Parallel applications based on TROPION-Lung01 and TROPION-Breast01 Phase III trial results demonstrating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan significantly improved progression-free survival vs. chemotherapy in two types of cancer The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment. The other MAA is for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) bre…
Company unveils new innovative Oncology organization, strategic vision and approach, following the Seagen acquisition in late 2023 Robust portfolio and R&D engine with 8+ potential blockbuster medicines by 2030 Multiple near- and mid-term catalysts expected to help drive long-term sustainable growth NEW YORK--(BUSINESS WIRE)-- At a meeting with the investment community today, Pfizer Inc. (NYSE: PFE) outlined its strategic priorities for the newly formed Oncology organization — and how its deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value. A replay of the webcast and related materials, including the presentations and a summary and transcript, w…
Today is Rare Disease Day, the official international awareness-raising campaign for rare diseases, observed annually on the last day of February. The primary goal of this campaign is to raise awareness among the general public and decision-makers about rare diseases and their influence on the lives of families living with these conditions. Rare Disease Day was launched by EURORDIS-Rare Diseases Europe and its Council of National Alliances in 2008. Did you know: 300 million people worldwide live with a rare disease There are over 6,000 different rare diseases 72% of rare diseases are genetic 70% of these genetic rare diseases begin in childhood. In total, there are around 300 million people worldwide living with a rare disease. Find out more about Rare Disease Day 2024: https://www.rared…
Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR)…
Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s…
Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.  Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information ser…
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“ REHOVOT, Israel and HEIDELBERG, Germany, February 20, 2024. AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel. AION Labs’ next startup will focus on the developm…
AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US. The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in-class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV), two leading causes of severe res…
Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability WALTHAM, Mass.--(BUSINESS WIRE)-- For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect. Thermo Fisher received five awards for capabilities, compatibility, expertise, and quality and reliability from three customer groups: big pharma, small pharma, and both. In total, customers evaluated 98 companies across 23 performance metrics for these honors, which distinguish the top contract manufacturing organizations by surveying leading global pharma and biotech companies. That research, based on the…
New Thermo Scientific Dionex Inuvion Ion Chromatography System streamlines ion analysis and expands analytical testing capabilities for ionic and small polar compounds WALTHAM, Mass.--(BUSINESS WIRE)-- To support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., today launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis. beverage labs with the necessary equipment to determine ionic contaminants in water. The technology also helps ident…
GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced,1 the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).2 AIO-001 has the potential to be administered every six months due to its high po…
PPD clinical research business provides lab customers a comprehensive solution to help ensure safe medicines for patients WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is adding mycoplasma and additional biosafety testing capabilities to its expanding portfolio of services at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients. “The continuing expansion of our GMP lab to include these new services further strengthens our ability to help our customers make the world healthie…
-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases -- FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC)…
The team will engineer cells to make membrane proteins efficiently The proteins will be used for drug discovery and screening, and as catalysts in sustainable chemical production The £1.8m Engineering Biology Mission Award has been given by UK Research and Innovation (UKRI) A team of academics from Aston University and the University of Warwick has secured a £1.8m grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication. The top ten selling medicines worldwide and multiple vaccines, including those for COVID-19, hepatitis B and whooping cough, target m…
Today, Boehringer Ingelheim and CBmed GmbH Center for Biomarker Research in Medicine (CBmed) announced a long-term strategic partnership. Jointly the partners will apply translational medicine approaches to accelerate the development of first-in-class medicines to transform the lives of people with cancer and achieve Boehringer’s ultimate ambition to cure a range of cancers. Precision medicine has revolutionized cancer care, offering great potential to cure more types of cancer. Still, 97 out of every 100 clinical trials testing compounds in a specific indication fail to demonstrate significant benefit for cancer patients.1 The reason is often a poor understanding of how or why a cancer treatment kills cancer cells directly or via activation of the immune system and which cancer patient…
CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine." Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna's board of directors since March 2011. In the 13 years since he joined Moderna, Mr. Bancel has led the company from startup to global commercial enterprise. Today, the Company has 45 mRNA therapeutic and vaccine programs in its pipeline, nine of…
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year. For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other Services category. The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets. Fortune® World's Most Admired Companies™ is the definitive report card on corporate reputation. Since 1997, Fortune® has identified, selected, and ranked the World’s Most Admi…